Edwards Lifesciences Corporation (EW) saw its stock price soar 5.50% in pre-market trading on Friday, following the release of impressive second-quarter 2025 financial results and an upward revision of its full-year guidance. The medical technology company's performance exceeded analyst expectations, driving investor optimism and fueling the significant stock price increase.

The company reported a robust 11.9% increase in Q2 sales, reaching $1.53 billion, surpassing analysts' estimates of $1.49 billion. Adjusted earnings per share (EPS) came in at $0.67, beating the consensus estimate of $0.62. Edwards Lifesciences' strong performance was driven by growth across its product lines, with Transcatheter Aortic Valve Replacement (TAVR) sales rising 8.9% to $1.13 billion, and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reaching $134.5 million.

In light of these strong results, Edwards Lifesciences raised its full-year 2025 guidance. The company now expects total sales growth of 9% to 10%, projecting revenues between $5.9 billion and $6.1 billion. Additionally, the company adjusted its underlying growth rate guidance for TAVR to 6% to 7%. The positive outlook, coupled with the Q2 earnings beat, appears to have fueled investor enthusiasm, leading to the significant pre-market stock price increase. The company's CEO, Bernard Zovighian, highlighted Edwards Lifesciences' balanced portfolio and leadership in aortic, mitral, and tricuspid therapies as key factors positioning the company for future growth.